Core Viewpoint - The company, Dajia Weikang (301126), is expected to report a loss in 2025 due to intensified industry competition and goodwill impairment, while its major shareholder plans to reduce its stake by up to 3% [1][2][3]. Group 1: Financial Performance - The company forecasts its 2025 revenue to be between 5.5 billion to 6 billion yuan, representing a year-on-year growth of 5.09% to 14.65% [2]. - The anticipated net loss for 2025 is projected to be between 250 million to 300 million yuan, primarily due to increased industry competition and goodwill impairment [2]. Group 2: Shareholder Actions - The controlling shareholder's concerted action party, Changsha Tongjia Investment Management Partnership, plans to reduce its holdings by no more than 6.16 million shares, which accounts for 3% of the total share capital, between March 10 and June 9, 2026 [3]. Group 3: Product Development Progress - The company is collaborating with Hunan University and other institutions to establish a clinical research center in the field of regenerative medicine, aiming to promote technology transfer [4]. - Ongoing product developments include the sodium salt of sacubitril/valsartan, which is in the technical review stage, and the application for ezetimibe/atorvastatin calcium tablets is being prepared, which may impact future business layout [4].
达嘉维康2025年业绩预亏，控股股东一致行动人拟减持